key: cord-0909440-tusb3evt authors: Kumar, Sanjeev; Chandele, Anmol; Sharma, Amit title: Current status of therapeutic monoclonal antibodies against SARS-CoV-2 date: 2021-09-03 journal: PLoS Pathog DOI: 10.1371/journal.ppat.1009885 sha: 08839108b020c03972c322443a72f8475492108b doc_id: 909440 cord_uid: tusb3evt nan epitopes on the S2 domain (stem helix region) of spike have also been identified that are broadly neutralizing, i.e., neutralize SARS-related and other human coronaviruses (hCoVs) [8] [9] [10] [11] . Therapeutic mAbs for COVID-19 treatment have been developed in accelerated time and the pace has been unprecedented for any disease. The approvals were obtained in a record time of only 10 months, including 3 to 4 months of clinical grade mAbs production since the discovery of mAbs [12] . Currently, 8 SARS-CoV-2 RBD-specific potent NAbs have been approved by the Food and Drug Administration (FDA) under an emergency use authorization (EUA) to treat COVID-19 nonhospitalized patients at high risk of severe illness. The following COVID-19 mAbs are in clinical use: bamlanivimab (LY-CoV555) [13] ; bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016 or JS016) [14] from Eli Lilly; casirivimab (REGN10933) and Imdevimab (REGN10987) [15] from Regeneron; cilgavimab (COV2-2130 or AZD1061) and tixagevimab (COV2-2196 or AZD8955) [16] from AstraZeneca; monotherapy-based NAbs sotrovimab (VIR-7831) [17] from GSK and Vir Biotechnology; and regdanvimab (CT-P59) [18] from Celltrion. Another set of monotherapy and combination Nabs-based therapies are under Phase III trials: 2B04 [19] and 47D11 [20] from AbbVie; BRII-196 and BRII-198 from Brii Biosciences [2] ; and TY027 from Tychan are also in Phase III trials [2] . A comprehensive list of NAbs that are currently in Phase I, II, and III trials and in clinic is summarized in Fig 2A. These therapeutic mAbs are used/administered in a range of 0.5 g to 1.2 g per dose, within 10 days of symptoms onset, as monotherapy or 2.4 g as a cocktail [21] [22] [23] . No dose-dependent effect was observed when these mAbs were tested at different doses (1.2 g to 8 g dose). The COVID-19 mAbs have demonstrated high efficacy in trials with a reduction of 70% to 85% in hospitalization or death [21, 23, 24] . Presently, these mAbs are used for intravenous administration; however, their intramuscular or subcutaneous administration testing is underway to facilitate larger access by overcoming the requirement of hospital settings. Presently, these mAbs are being produced in large-scale bioreactors of 15,000 L capacity, sufficient to provide 100 to 200,000 doses [12, 25] . However, a single-dose regimen of these therapeutic mAbs continues to be expensive, particularly for low-and middle-income countries. Several SARS-CoV-2 variants are being reported from different parts of the world. According to the World Health Organization (WHO), a recognized mutation is elevated to a "variant of concern" (VOC) when the acquisition of a new mutation allows for increased viral transmission, increased fatality, and a significant decrease in the effectiveness of therapy and vaccines. PLOS PATHOGENS [27] , Gamma (P.1, identified in Brazil) [28] , and Delta (B.1.617.2, identified in India) [29] . The VOIs are Eta (B.1.525, identified in UK/Nigeria), Iota (B.1.526, identified in the United States of America) [30] , Kappa (B.1.617.1, identified in India) [29] , and Lambda (C.37, identified in Peru) [31] (Fig 2B) . Recently, Epsilon (B.1.427/429, identified in the USA) [32] , Zeta (P.2, identified in Brazil), and Theta (P.3, identified in the Philippines) [33] variants have been excluded from the category of VOIs by WHO due to their declining prevalence. Ideally, an effective antiviral therapeutic strategy should have the ability to prevent infection/disease by new variants while simultaneously maintaining breadth against existing multiple viral strains/ variants. Recent studies have reported that many NTD-specific NAbs are relatively less effective to all emerging variants, whereas RBD-specific NAbs are variably effective against emerging variants and VOCs [2, 34, 35] . The majority of the potent therapeutic NAbs as monotherapy showed complete abrogation or reduced neutralizing activity against SARS-CoV-2 emerging variants that contain the E484K/Q or L452R mutations [34] [35] [36] [37] . Bamlanivimab (LY-CoV555) was ineffective against all VOCs and thus was no longer considered for EUA. Currently, combination therapies comprising a cocktail of NAbs targeting distinct nonoverlapping epitopes on RBD have demonstrated exceptional potency and promising correlates of protection against SARS-CoV-2 and its variants (Fig 2B) [36, 38] . Additionally, newly identified RBD core-binding NAbs SARS2-38 [39] and LY-CoV1404 [40] as monotherapy potently neutralize all SARS-CoV-2 VOCs. Therefore, several options of NAbs targeting conserved RBD epitopes are emerging as promising and attractive therapeutic candidates to tackle the disease burden caused by SARS-CoV-2 or its variants. Although anti-viral functions of NAbs against rapidly emerging variants are being studied extensively, there is also a need to focus on understanding the role of the Fc portion of NAbs in providing protection against SARS-CoV-2 and emerging variants. The role of the Fc region is secondary when NAbs are administered as prophylaxis, but is critical for optimal therapeutic protection. A recent study demonstrated that therapeutic NAbs (REGN, Abbvie, AstraZeneca, and Vir Biotechnology) with intact Fc region reduced viral load and lung disease in animal models in comparison to NAbs without Fc effector functions (LALA-PG mutation) [41] . It is well appreciated that for optimal in vivo protection, NAbs with intact Fc region can mediate downstream effector functions via interaction with Fc receptors resulting in antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis. Moreover, Fcmediated complement activation can exert a broad range of immunomodulatory functions, with activation of C1q resulting in antibody-mediated complement activation, and complement-dependent cytotoxicity. However, a recent study showed the diminished role of the Fc region in protecting against lethal SARS-CoV-2 infections in K18-hACE2 transgenic mice [42] . This study showed that potent NAbs do not rely on Fc effector functions to provide optimal protection when administered as therapy. Moreover, the role of Fc-mediated antibody-dependent enhancement (ADE) observed in vitro is yet to be fully elucidated in vivo [43, 44] . Recently, a few bispecific NAbs have been developed by combining the antibody chains of 2 independent nonoverlapping antibodies [45, 46] . These bispecific NAbs neutralize wild-type SARS-CoV-2, its VOCs, and escape mutants and have shown to be protective in mice models. This suggests that bispecific NAbs are promising next-generation cost-effective therapeutics against SARS-CoV-2 and its VOCs. Such variant-resistant next-generation or combination of broadly reactive ultrapotent NAbs-based safe therapeutics are desperately needed globally. These mAb-based therapeutics should be globally accessible and affordable in low-middle income countries where more than of 85% human populations reside. Therefore, the development of a panel of well-characterized, clinically developable ultrapotent NAbs could be established rapidly to combat current and rapidly emerging SARS-CoV-2 variants. Here we have summarized the current status of mAb-based therapy for COVID-19 and have shed light on the ongoing development of mAbs-based therapeutics against emerging SARS-CoV-2 variants. Due to the potential of newly emerging SARS-CoV-2 variants in the future, vaccines will need to be constantly reassessed for their efficacy. The mAb biotherapeutics are a promising strategy for immediate treatment/prophylaxis or in situations where vaccines are less effective-such as in immunocompromised individuals, young, elderly, and vaccine-hesitant individuals. MAbs can also be rapidly tailored, selected, or mined towards new variants. For this, we need more intensive studies to track viral evolution, analyze the human antibody repertoire, identify and develop pan-coronavirus NAbs that target evolutionarily conserved epitopes. These efforts will enable rapid and dynamic reconfiguration of existing NAb cocktails to cull new surges that are driven by SARS-CoV-2 variants. CoV-AbDab: the coronavirus antibody database. Bioinformatics Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses Tackling COVID-19 with neutralizing monoclonal antibodies Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection Developing therapeutic monoclonal antibodies at pandemic pace Antibody for COVID-19 An EUA for casirivimab and imdevimab for COVID-19. Med Lett Drugs Ther Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection A human monoclonal antibody blocking SARS-CoV-2 infection SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. medRxiv Process and operations strategies to enable global access to antibody therapies Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil SARS-CoV-2 variants of concern are emerging in India Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. bioRxiv First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil. medRxiv SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv SARS-CoV-2 variants, spike mutat,ions, and immune escape Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Res Sq Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals. bioRxiv A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope. bioRxiv LY-CoV1404 potently neutralizes SARS-CoV-2 variants. bioRxiv Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies. bioRxiv The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv